Panelists on stage at the Global HPV Consortium

The Global HPV Consortium

A public-private movement to prevent Human Papilloma Virus (HPV) infection and eliminate cervical cancer as a public health concern.

An increased sense of urgency is needed as the world falls behind

Since introduction in 2006, HPV vaccines have proven safe and effective in protecting against infection and preventing cervical cancer. Yet, the burden of HPV diseases continues to rise with an estimated 600,000 new cases of cervical cancer and over 340,000 deaths each year.

To respond to these life-threatening trends, the Sabin Vaccine Institute, as consortium secretariat, along with a diverse, and expanding, set of partners will mobilize action across three pillars:

The Global HPV Consortium will be guided by global goals, including WHO’s Immunization Agenda 2030 and Cervical Cancer Elimination Initiative:

Who We Are

The Action Plan will include impactful and actionable steps to deliver on the promise of protection against the devastating effects of HPV through primary and secondary prevention.

The Plan will:
  • Be informed by a sustained and dynamic community of global, national and sub-national stakeholders.
  • Encompass issues from political commitment, financing, policy, through to community-level service delivery.
  • Promote an on-the-ground alliance and convergence of multi-sectoral actors and institutions.
  • Spotlight the voices of women, young people, and those most vulnerable to HPV and cervical cancer.
  • Listen to and learn from communities about their needs and aspirations and activate impactful response.
  • Spur and scale-up local innovation.

The Plan’s actionable framework will deliver on the promise of protection from HPV and cervical cancer by:

  • Establishing feedback loops from global to sub-national levels for connection and accountability
  • Dynamically distilling & disseminating best practices
  • Applying a social & behavioral lens to HPV vaccine acceptance and demand challenges & solutions
  • Fostering adaptive service delivery and leadership throughout the value chain
  • Driving investment in innovation & impact
  • Generating new knowledge and evidence